Cell MedX Corp (NASDAQ:CMXC) CEO Frank Mcenulty acquired 481,016 shares of Cell MedX Corp stock in a transaction that occurred on Thursday, October 12th. The shares were bought at an average price of $0.25 per share, with a total value of $120,254.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Cell MedX Corp (NASDAQ CMXC) traded down 3.417356% during mid-day trading on Friday, reaching $0.289265. The company’s stock had a trading volume of 845 shares. Cell MedX Corp has a 12 month low of $0.15 and a 12 month high of $0.48. The firm’s market capitalization is $12.74 million. The company has a 50 day moving average of $0.29 and a 200-day moving average of $0.30.
ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/27/cell-medx-corp-cmxc-ceo-buys-120254-00-in-stock.html.
Cell MedX Corp Company Profile
Cell MedX Corp. is a development-stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases, such as diabetes, by developing technologies to help manage the illness and related complications. The Company, through its subsidiary, Avyonce Cosmedics Inc (Avyonce), is engaged in reselling and marketing spa technology and equipment to the beauty and wellness industry.
Receive News & Ratings for Cell MedX Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cell MedX Corp and related companies with MarketBeat.com's FREE daily email newsletter.